Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Phys Vivascardiovascular

Phys Vivas · cardiovascular

Anticoagulation and Antiplatelet Therapy — Viva Defence

Structured DCE viva: defending anticoagulation in an elderly patient with atrial fibrillation, recurrent falls and chronic kidney disease — risk quantification, agent choice, and the probing questions examiners actually ask.

4 min readVerification in progress

Target exams

FRACP DCEMRCP Part 2
On this page
Study tools

Target exams

FRACP DCEMRCP Part 2
Prompt
Structured DCE viva: defending anticoagulation in an elderly patient with atrial fibrillation, recurrent falls and chronic kidney disease — risk quantification, agent choice, and the probing questions examiners actually ask.

Opening statement (SASPOP, delivered aloud)

"Mrs Brooks is an 82-year-old retired teacher with persistent atrial fibrillation and a CHA₂DS₂-VASc score of at least 4, giving her a substantial annual stroke risk — on the background of stage 3 chronic kidney disease and recurrent falls, one injurious. Her anticoagulation was stopped after a fall, converting a managed bleeding risk into an unmanaged stroke risk. Her problems are: cardioembolic stroke risk that is currently untreated; CKD, which constrains agent choice and mandates scheduled renal review; a falls syndrome that needs its own workup and treatment; and a family whose fear of bleeding needs respectful, numerical answering. My goal today is to re-establish safe anticoagulation with the lowest-bleeding agent her kidneys allow, and to treat the falls rather than surrendering to them." [1] [3]

Physician Medicine Pro

Continue reading

You have read the opening of this viva. The complete unit — every section and its primary-source references — is part of the Physician Medicine fellowship library.

Sign in to continueSee pricing
References5ShowHide
  1. [1]Man-Son-Hing M, Nichol G, Lau A, et al. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls Arch Intern Med, 1999.PMID 10218746
  2. [2]Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med, 2011.PMID 21870978
  3. [3]Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation Chest, 2010.PMID 19762550
  4. [4]Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey Chest, 2010.PMID 20299623
  5. [5]Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med, 2009.PMID 19717844
Physician Medicine Pro

$29/ monthor $279 / year

The complete Physician Medicine library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousAdult Congenital Heart Disease — Viva DefencecardiovascularNextAortic Disease — Viva Defencecardiovascular